European Pharmacogenetics of Anticoagulant Therapy–Warfarin - EU-PACT Warfarin

Description:

Although warfarin remains the most commonly used agent for treatment of atrial fibrillation (AF) and venous thromboembolism (VTE), it has a narrow therapeutic index, with wide variation among patients in the daily doses required. Although a number of factors are responsible, pharmacogenomic studies have identified that two genes, CYP2C9 (cytochrome p450 isoform) and VKORC1 (vitamin K epoxide reductase complex subunit 1), account for a large portion of this variability. The curr...